$0.89+0.03 (+3.99%)
Quantum-Si incorporated, a life sciences company, develops proprietary, universal, and single-molecule detection platform applied to proteomics to enable next-gen protein sequencing (NGPS).
Quantum-Si incorporated in the Healthcare sector is trading at $0.89 with a market capitalization of $207M. Wall Street consensus targets $2.50 (3 analysts), implying a +181.2% move over the next 12 months. The stock is currently near its 52-week low of $0.69, remaining 27.7% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $258,000β | $451,000β | $552,000β | $591,000β | $842,000 |
| Gross Profit | $74,000β | $122,000β | $194,000β | $351,000β | $486,000 |
| Operating Income | -$24.05Mβ | -$21.09Mβ | -$24.40Mβ | -$26.76Mβ | -$25.11M |
| Net Income | -$21.67Mβ | -$17.61Mβ | -$35.70Mβ | -$28.84Mβ | -$19.19M |
Quantum-Si incorporated, a life sciences company, develops proprietary, universal, and single-molecule detection platform applied to proteomics to enable next-gen protein sequencing (NGPS). The company offers Platinum and Platinum Pro NGPS instrument...
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Quantum-Si (NASDAQ:QSI) reported first-quarter 2026 revenue of $258,000 and reiterated that the year will be a transition period focused on development and market preparation for its next-generation Proteus protein sequencing platform. President and Chief Executive Officer Jeff Hawkins said the com
Moby summary of Quantum-Si incorporated's Q1 2026 earnings call
QuantumSi Incorporated (QSI) delivered earnings and revenue surprises of +16.67% and -35.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Joining me today are Jeffrey Alan Hawkins, our President and Chief Executive Officer, as well as Jeffry R. Keyes, our Chief Financial Officer. The results of this progress were highlighted in our recent announcement regarding the successful completion of sequencing on fully integrated Proteus instruments.